EVH
Evolent Health, Inc.
EVH offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over EVH overall, supported by stronger fundamentals and lower modeled downside.
EVH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Stable | |
| Weak |
EVH's revenue is currently healthy, and its cash flow is stable, but its profitability and balance sheet are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
EVH PE Valuation
EVH has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
EVH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for EVH, with profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over EVH on the outlook, with more favorable profitability expectations.
EVH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.40 | — |
| Q3 2026 | -$4.54 | -$2.96 |
| Q2 2026 | -$4.57 | -$2.96 |
| Q1 2026 | -$4.76 | -$3.53 |
| Q4 2025 | -$5.15 | -$4.33 |
| Q3 2025 | -$1.58 | -$0.67 |
| Q2 2025 | -$1.61 | -$0.67 |
| Q1 2025 | -$1.23 | +$0.02 |
| Q4 2024 | -$0.82 | +$0.45 |
EVH is still losing money, but less than at its worst: $4.54 per share over the past year, against $6.11 at its worst in late 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over EVH on earnings quality, reporting a profit while its opponent remains loss making.
EVH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $725.4M | +51% |
| Q2 2026 | $652.5M | +47% |
| Q1 2026 | $496.2M | +2.6% |
| Q4 2025 | $468.7M | -28% |
| Q3 2025 | $479.5M | -23% |
| Q2 2025 | $444.3M | -31% |
| Q1 2025 | $483.6M | -24% |
| Q4 2024 | $646.5M | +16% |
EVH's revenue is growing: $725M last quarter, up 51% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | -1 points |
| Q2 2026 | -1.5% | -1.2 points |
| Q1 2026 | -2.1% | -1.8 points |
| Q4 2025 | -87% | -84 points |
| Q3 2025 | 0.2% | +2.8 points |
| Q2 2025 | -0.3% | -1.5 points |
| Q1 2025 | -0.3% | +1.8 points |
| Q4 2024 | -2.9% | +1 points |
EVH's operating margin was −0.8% last quarter, down 1 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over EVH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over EVH on profitability, with a higher operating margin.
EVH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26.4M | +67% |
| Q2 2026 | -$9.3M | +$21M |
| Q1 2026 | -$984K | -122% |
| Q4 2025 | $48.8M | +$75M |
| Q3 2025 | $15.8M | -15% |
| Q2 2025 | -$30.3M | -242% |
| Q1 2025 | $4.6M | -7% |
| Q4 2024 | -$26.2M | -129% |
EVH's free cash flow has turned positive again: $65M over the past year, against −$36M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over EVH on cash flow, with more consistent year-over-year improvement.
EVH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +529K shares |
| 1 year | -0.9% | -995K shares |
| 3 years | +0.7% | +789K shares |
| 5 years | +32% | +27.3M shares |
| Available history | +37% | +30.7M shares |
EVH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
EVH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 11.9x | High |
| Q2 2025 | 9.8x | High |
| Q1 2025 | 6.8x | High |
| Q4 2024 | 7.2x | High |
| Q3 2024 | 6.7x | High |
| Q2 2024 | 6.5x | High |
| Q1 2024 | 8.8x | High |
| Q4 2023 | 7.7x | High |
EVH's net debt is about 12 years of its operating earnings (EBITDA), up from 6.7 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
EVH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 72.6 | Neutral |
EVH's weekly RSI is 54 (neutral) and its Stochastic is 73 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
EVH PE vs Healthcare Sector
EVH has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
EVH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.27 | 12% above |
| 20 week MA | $4.45 | 7.2% above |
| 50 week MA | $3.92 | 22% above |
| 100 week MA | $6.50 | 27% below |
| 200 week MA | $17.2 | 72% below |
EVH has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 72% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over EVH on trend strength, trading above more of its moving averages.
EVH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.85 | $16.3 | +84% |
| 2021 | $16.3 | $27.0 | +66% |
| 2022 | $27.0 | $27.3 | +1.3% |
| 2023 | $27.3 | $33.0 | +21% |
| 2024 | $33.0 | $11.1 | -66% |
| 2025 | $11.1 | $4.12 | -63% |
| 2026 YTD | $4.12 | $4.77 | +16% |
EVH has finished higher in four of the last six years, two of them by more than 50%. It's up 16% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over EVH on returns for 2026, with the stronger performance.